PrimeLink Bio announced that it has received $28 million in funding from Shanghai Fosun Pharmaceutical Co., Ltd., Hangzhou Kaitai Capital Co., Ltd., Vertex Ventures China

other

▤ Summary

PrimeLink Bio announced that it has raised $28 million in a round of funding co-led by Hangzhou Kaitai Capital Co. and Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on November 25, 2022. The transaction also included participation from Vertex Ventures China.

▥ Classifications

industries
No industries detected
applications
No applications detected

◇ AskAI Classifications

Labels
No AI classifications detected

▦ Linked Companies